Novavax (NASDAQ: NVAX) has been one of the more promising COVID-19 vaccine stocks to invest in since the pandemic began. But while rival Moderna (NASDAQ: MRNA) has been generating billions in revenue from its vaccine, Novavax continues to wait for an Emergency Use Authorization in the U.S. market.
There's still hope for Novavax to grab some market share, especially with the Food and Drug Administration (FDA) recently permitting a second booster shot for individuals 50 and over and those with weakened immune systems. As Novavax's share price continues falling to new lows, investors may see the risk-reward ratio become a bit more tenable.
Image source: Getty Images.
Source Fool.com